Multivariate analyses models for response and survival after induction chemotherapy in MDS patients experiencing HMA failure
Variable . | ORR, % . | OR . | 95% CI . | P . |
---|---|---|---|---|
Age, y | 0.28-0.78 | <.01 | ||
<65 | 48 | 1 | ||
≥65 | 34 | 0.47 | ||
Cytogenetic risk | 0.25-0.83 | .01 | ||
Favorable/intermediate | 47 | 1 | ||
Unfavorable | 29 | 0.46 | ||
IPSS | 0.311-1.15 | .12 | ||
Int-2 or lower | 45 | 1 | ||
High | 30 | 0.60 | ||
Therapy related | 0.25-1.20 | .13 | ||
No | 43 | 1 | ||
Yes | 28 | 0.55 | ||
Induction regimen | 1.24-6.90 | .01 | ||
Other (7+3 or PNA) | 37 | 1 | ||
IDAC | 64 | 2.91 |
Variable . | ORR, % . | OR . | 95% CI . | P . |
---|---|---|---|---|
Age, y | 0.28-0.78 | <.01 | ||
<65 | 48 | 1 | ||
≥65 | 34 | 0.47 | ||
Cytogenetic risk | 0.25-0.83 | .01 | ||
Favorable/intermediate | 47 | 1 | ||
Unfavorable | 29 | 0.46 | ||
IPSS | 0.311-1.15 | .12 | ||
Int-2 or lower | 45 | 1 | ||
High | 30 | 0.60 | ||
Therapy related | 0.25-1.20 | .13 | ||
No | 43 | 1 | ||
Yes | 28 | 0.55 | ||
Induction regimen | 1.24-6.90 | .01 | ||
Other (7+3 or PNA) | 37 | 1 | ||
IDAC | 64 | 2.91 |
Variable . | Median OS, mo . | HR . | 95% CI . | P . |
---|---|---|---|---|
Cytogenetic risk | 0.99-2.06 | .06 | ||
Favorable/intermediate | 15.6 | 1 | ||
Unfavorable | 8.1 | 1.43 | ||
Disease status at HMA failure | 0.95-2.24 | .09 | ||
Stable | 13.6 | 1 | ||
Progressive | 10.5 | 1.46 |
Variable . | Median OS, mo . | HR . | 95% CI . | P . |
---|---|---|---|---|
Cytogenetic risk | 0.99-2.06 | .06 | ||
Favorable/intermediate | 15.6 | 1 | ||
Unfavorable | 8.1 | 1.43 | ||
Disease status at HMA failure | 0.95-2.24 | .09 | ||
Stable | 13.6 | 1 | ||
Progressive | 10.5 | 1.46 |
Logistic regression multivariate analysis model for multivariate analysis of overall response and Cox model for multivariate analysis of OS after induction therapy, including all covariates with a potential outcome on response in univariate analysis (P value in univariate <.15). Cytogenetic risk was evaluated per MDS IPSS classification.
OR, odds ratio.